Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Act Therapeutics Ltd. manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to SAMALA, JAGADISHWAR RAO, who is also the busiest examiner for the portfolio with 1 pending action. The concentration of work is high, as the portfolio involves only 1 distinct examiner and 1 distinct art unit.
This narrow distribution suggests a highly focused prosecution strategy or a very early-stage portfolio. Because all activity is limited to 1 distinct art unit, the company faces a singular set of examination standards and procedural norms. Practitioners should note that the entire pending workload rests with SAMALA, JAGADISHWAR RAO, making this individual the primary point of contact for the company's current patent efforts.
The lack of diversity in examiners means the portfolio's progress is entirely dependent on the specific throughput and tendencies of a single office official. For a company in Biotechnology & Pharmaceuticals, this centralization can simplify communication but increases the impact of a single examiner's perspective. This structure requires precise alignment with the examiner's technical interpretations to ensure successful outcomes across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAMALA, JAGADISHWAR RAO | 1 | 67.9% | +55.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556646 | ENHANCEMENT OF TREATMENT WITH IMMUNOTHERAPEUTIC AGENTS | SAMALA, JAGADISHWAR RAO | 26d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556646 | ENHANCEMENT OF TREATMENT WITH IMMUNOTHERAPEUTIC AGENTS | SAMALA, JAGADISHWAR RAO | 26d overdue |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556646 | ENHANCEMENT OF TREATMENT WITH IMMUNOTHERAPEUTIC AGENTS | SAMALA, JAGADISHWAR RAO | 1618 | §103§112 | Non-Final OA | 26d overdue | Pending | Oct 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAct Therapeutics Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jagadishwar Rao Samala has the most, with 1 of Act Therapeutics Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
